Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis.

Gwangwa MV, Joubert AM, Visagie MH.

Cell Mol Biol Lett. 2018 May 4;23:20. doi: 10.1186/s11658-018-0088-y. eCollection 2018. Review.

2.

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.

Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G.

Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3.

3.

Conditioning neoadjuvant therapies for improved immunotherapy of cancer.

Benson Z, Manjili SH, Habibi M, Guruli G, Toor AA, Payne KK, Manjili MH.

Biochem Pharmacol. 2017 Dec 1;145:12-17. doi: 10.1016/j.bcp.2017.08.007. Epub 2017 Aug 10. Review.

PMID:
28803721
4.

Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells.

Garziera M, Scarabel L, Toffoli G.

J Immunol Res. 2017;2017:4587520. doi: 10.1155/2017/4587520. Epub 2017 Jul 11. Review.

5.

Hypoxia as a target for drug combination therapy of liver cancer.

Bowyer C, Lewis AL, Lloyd AW, Phillips GJ, Macfarlane WM.

Anticancer Drugs. 2017 Aug;28(7):771-780. doi: 10.1097/CAD.0000000000000516.

6.

Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB.

D'Ignazio L, Batie M, Rocha S.

Biomedicines. 2017 May 9;5(2). pii: E21. doi: 10.3390/biomedicines5020021. Review.

7.

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.

Pang Y, Yang C, Schovanek J, Wang H, Bullova P, Caisova V, Gupta G, Wolf KI, Semenza GL, Zhuang Z, Pacak K.

Oncotarget. 2017 Apr 4;8(14):22313-22324. doi: 10.18632/oncotarget.16224.

8.

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.

Yu T, Tang B, Sun X.

Yonsei Med J. 2017 May;58(3):489-496. doi: 10.3349/ymj.2017.58.3.489. Review.

9.

Systems biology of oxygen homeostasis.

Samanta D, Prabhakar NR, Semenza GL.

Wiley Interdiscip Rev Syst Biol Med. 2017 Jul;9(4). doi: 10.1002/wsbm.1382. Epub 2017 Feb 21. Review.

10.

Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.

Kim J, de Sampaio PC, Lundy DM, Peng Q, Evans KW, Sugimoto H, Gagea M, Kienast Y, do Amaral NS, Rocha RM, Eikesdal HP, Lønning PE, Meric-Bernstam F, LeBleu VS.

JCI Insight. 2016 Dec 22;1(21):e90733. doi: 10.1172/jci.insight.90733.

11.

The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization.

Zeng M, Shen J, Liu Y, Lu LY, Ding K, Fortmann SD, Khan M, Wang J, Hackett SF, Semenza GL, Campochiaro PA.

J Mol Med (Berl). 2017 Apr;95(4):417-429. doi: 10.1007/s00109-016-1498-9. Epub 2016 Dec 21.

12.

Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.

Wu W, Cao J, Ji Z, Wang J, Jiang T, Ding H.

Oncotarget. 2016 Dec 6;7(49):81144-81155. doi: 10.18632/oncotarget.13214.

13.

Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models.

Phelan JP, Reen FJ, Dunphy N, O'Connor R, O'Gara F.

BMC Cancer. 2016 Jul 14;16:476. doi: 10.1186/s12885-016-2528-2.

14.

Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.

Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS.

Oncotarget. 2016 Jul 12;7(28):42844-42858. doi: 10.18632/oncotarget.10212.

15.

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M.

Am J Hematol. 2016 Aug;91(8):800-5. doi: 10.1002/ajh.24415. Epub 2016 Jun 25.

16.

Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.

Hu K, Babapoor-Farrokhran S, Rodrigues M, Deshpande M, Puchner B, Kashiwabuchi F, Hassan SJ, Asnaghi L, Handa JT, Merbs S, Eberhart CG, Semenza GL, Montaner S, Sodhi A.

Oncotarget. 2016 Feb 16;7(7):7816-28. doi: 10.18632/oncotarget.6868.

17.

An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors.

Szablowski JO, Raskatov JA, Dervan PB.

Mol Cancer Ther. 2016 Apr;15(4):608-17. doi: 10.1158/1535-7163.MCT-15-0719. Epub 2015 Dec 30.

18.

The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Sun Z, Schriewer J, Tang M, Marlin J, Taylor F, Shohet RV, Konorev EA.

J Mol Cell Cardiol. 2016 Jan;90:129-38. doi: 10.1016/j.yjmcc.2015.12.010. Epub 2015 Dec 11.

19.

HIF-1α pathway: role, regulation and intervention for cancer therapy.

Masoud GN, Li W.

Acta Pharm Sin B. 2015 Sep;5(5):378-89. doi: 10.1016/j.apsb.2015.05.007. Epub 2015 Jun 6. Review.

20.

Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells.

Chen S, Sang N.

J Cell Biochem. 2016 Feb;117(2):267-78. doi: 10.1002/jcb.25283. Review.

Supplemental Content

Support Center